Table 2

Optimal MTX dose and comorbidities/toxic effects

Comorbidities/toxicitiesOptimal MTX dose*
(n=76)
Non-optimal MTX dose (n=212)p
At baseline
Transaminitis, n (%)
  AST≤30 U/L6 (7.9%)24 (11.5%)0.514
  30 U/L<AST<60 U/L69 (90.8%)187 (88%)0.672
  AST≥60 U/L1 (1.3%)1 (0.48%)0.459
  AST≥90 U/L0 (0%)1 (0.48%)1
  ALT≤35 U/L7 (9.2%)24 (11.5%)0.673
  35 U/L<ALT<70 U/L69 (90.8%)186 (87.5%)0.536
  ALT≥70 U/L0 (0%)2 (0.96%)1
  ALT≥105 U/L0 (0%)1 (0.48%)1
γ-GT≤45 U/L20 (26.3%)61 (29.6%)0.767
γ-GT level, U/L37.7±42.243.3±54.40.416
Blood creatinine level, μmol/L77.0±17.572.9±16.80.072
Severe gastrointestinal events (haemorrhage, perforation, ulcer)2 (2.6%)15 (7.1%)0.255
Bronchitis and chronic obstructive pulmonary disease1 (1.3%)0 (0%)0.264
At M6
Transaminitis, n (%)
  AST≤30 U/L6 (7.9%)36 (17.2%)0.059
  30 U/L<AST<60 U/L69 (90.8%)172 (81.1%)0.069
  AST≥60 U/L1 (1.3%)4 (1.91%)1
  AST≥90 U/L0 (0%)0 (0%)1
  ALT≤35 U/L7 (9.2%)39 (18.6%)0.069
  35 U/L<ALT<70 U/L69 (90.8%)167 (78.8%)0.023
  ALT≥70 U/L0 (0%)6 (2.86%)0.346
  ALT≥105 U/L0 (0%)4 (1.9%)0.576
Severe gastrointestinal events (haemorrhage, perforation, ulcer)0 (0%)3 (1.4%)0.569
Bronchitis and chronic obstructive pulmonary disease1 (1.3%)0 (0%)0.264
  • *Data are mean±SD or n (%). Significant results are in bold type.

  • ALT, alanine transaminase; AST, aspartate transaminase; M6, 6 months; MTX, methotrexate; γ-GT, gamma-glutamyltranspeptidase.